# Enicepatide dose guide & dosage chart | PepVault

Source: https://pepvault.app/lab/dosage/enicepatide

Last updated: 2026-10-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

## Enicepatide dosage

A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened. Commonly reported: in trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.

- **Dose range:** 4–24 mg (research range). Trials and labels start at 2 mg and step up. Studied in research — not a recommendation.
- **How often:** Weekly
- **A typical run:** Ongoing. Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it.
- **How it’s taken:** Vial: SubQ injection
- **Evidence:** Moderate: Animal studies + some human data
- **Half-life:** ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)

### Enicepatide on your syringe

With a 10 mg vial and 2 mL of water (5 mg in every mL), on a 1 mL (100-unit) U-100 insulin syringe: the low end, 4 mg, is 80 units; and the high end, 24 mg, needs more than this vial holds. 2 doses in the vial at the low end. All U-100: 100 units to the mL. A U-40 syringe reads differently.

[Enicepatide in the peptide library](https://pepvault.app/peptides/enicepatide) [The Dose Guide: every peptide](https://pepvault.app/lab/dosage)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

<!--promo-->

## Track the doses you run

PepVault logs every dose, keeps count of the doses left in your vials, and reminds you on your schedule.

[Get PepVault on the App Store](https://apps.apple.com/app/id6779318649?pt=129020030&ct=lab-dosage-text&mt=8) 7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More glp-1 & metabolic peptides

- [Semaglutide](https://pepvault.app/lab/dosage/semaglutide) 0.25–2.4 mg
- [Semaglutide (oral)](https://pepvault.app/lab/dosage/semaglutide-oral) 1.5–25 mg
- [Tirzepatide](https://pepvault.app/lab/dosage/tirzepatide) 2.5–15 mg
- [Retatrutide](https://pepvault.app/lab/dosage/retatrutide) 1–12 mg
- [Liraglutide](https://pepvault.app/lab/dosage/liraglutide) 0.6–3 mg
- [Dulaglutide](https://pepvault.app/lab/dosage/dulaglutide) 0.75–4.5 mg
- [Exenatide](https://pepvault.app/lab/dosage/exenatide) 5–10 mcg
- [Setmelanotide](https://pepvault.app/lab/dosage/setmelanotide) 0.5–3 mg
- [Orforglipron](https://pepvault.app/lab/dosage/orforglipron) 0.8–17.2 mg
- [Survodutide](https://pepvault.app/lab/dosage/survodutide) 0.3–6 mg
- [Mazdutide](https://pepvault.app/lab/dosage/mazdutide) 2–6 mg
- [Pemvidutide](https://pepvault.app/lab/dosage/pemvidutide) 1.2–2.4 mg
- [Cagrilintide](https://pepvault.app/lab/dosage/cagrilintide) 0.25–2.4 mg
- [Pramlintide](https://pepvault.app/lab/dosage/pramlintide) 15–120 mcg
- [CagriSema](https://pepvault.app/lab/dosage/cagrisema) 0.25–2.4 mg
- [Eloralintide](https://pepvault.app/lab/dosage/eloralintide) 1–9 mg
- [Petrelintide](https://pepvault.app/lab/dosage/petrelintide) 1–9 mg
- [Amycretin](https://pepvault.app/lab/dosage/amycretin) 0.4–60 mg
- [VK2735](https://pepvault.app/lab/dosage/vk2735) 2.5–17.5 mg
- [Ecnoglutide](https://pepvault.app/lab/dosage/ecnoglutide) 0.6–2.4 mg
- [Efinopegdutide](https://pepvault.app/lab/dosage/efinopegdutide) 4–10 mg
- [5-Amino-1MQ](https://pepvault.app/lab/dosage/5-amino-1mq) 50–100 mg
- [SLU-PP-332](https://pepvault.app/lab/dosage/slu-pp-332) 250–1000 mcg
- [Oxytocin](https://pepvault.app/lab/dosage/oxytocin) 10–40 IU

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.
